WO1991009974A1 - Sonde de diagnostic servant a detecter les cancers de l'estomac chez l'homme - Google Patents

Sonde de diagnostic servant a detecter les cancers de l'estomac chez l'homme Download PDF

Info

Publication number
WO1991009974A1
WO1991009974A1 PCT/US1990/007313 US9007313W WO9109974A1 WO 1991009974 A1 WO1991009974 A1 WO 1991009974A1 US 9007313 W US9007313 W US 9007313W WO 9109974 A1 WO9109974 A1 WO 9109974A1
Authority
WO
WIPO (PCT)
Prior art keywords
met gene
gene product
met
antibody
human stomach
Prior art date
Application number
PCT/US1990/007313
Other languages
English (en)
Inventor
Thomas Edward Kmiecik
George Franklin Vande Woude
Original Assignee
The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce filed Critical The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce
Priority to CA002070995A priority Critical patent/CA2070995A1/fr
Publication of WO1991009974A1 publication Critical patent/WO1991009974A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Definitions

  • oncogene and proto-oncogene probes have been reported to be useful in diagnostic procedures for detecting certain forms of cancer and for following disease prognosis.
  • a specific probe for the diagnosis of human stomach cancer has not heretofore been known or described.
  • an object of the present invention to provide specific probes for detecting human stomach cancer.
  • Such a unique probe came into being by the unexpected finding that the met proto- oncogene was activated in certain human cancer cell lines tested.
  • the characteristics of the met gene can be found described in Park et al, 1986, Cell f 45:895- 904; Park et al, 1987, PNAS. 84:6379-6383 and Gonzatti- Haces et al, 1988, PNAS. 85:21-25.
  • Geno ic DNA from the HOS line and several gastric carcinoma cell lines were digested with EcoRI, fractionated on a 1% agarose gel, and transferred to nitrocellulose. The blot was baked for 2 hours. The blot was prehybridized for 4 hours at 42°C. The prehybridization and hybridization was in 50% formamide, 5x Denhardts, 200 ⁇ g/ml salmon sperm DNA, 5x SSPE, and 0.1% SDS. The blot was washed with 2x SSC, 0.1% SDS for 20 minutes at RT, then with 3 washes of 0.2 X SSC, 0.1% SDS at 68°C.
  • a deposit of the hybridoma producing monoclonal antibody having specificity to the met oncogene product has been made at the ATCC, Rockville, MD. , on December 14, 1989 under accession number HB 10309. The deposit shall be viably maintained, replacing if it becomes
  • FIG. 1 shows the gene copy number in gastric carcinoma cell lines as determined by Southern blot. A fragment representing most of the met cDNA was used to probe genomic DNA which had been digested with EcoRI. Several hybridizing bands are detected. The MKN-45 and Okajima cell lines show significant amplification of the met gene. No rearrangement is detected with this probe. To further confirm these results, RNA levels were examined by Northern blot. Total RNA from several cell lines was probed with a fragment containing the met extracellular domain. A 9 kb met RNA is detected in all cell lines. As shown in Fig. 2, the met RNA is greatly overexpressed in the MKN-45 and Okajima cell lines.
  • a diagnostic kit for the detection of met gene product comprises a container containing antibodies to the met gene product.
  • a nucleic acid or polypeptide probe for detecting the met gene or the met gene product is easily made by conventional methodologies well known to one of ordinary skill in the art. Nucleic acid probes useful for this purpose are described in Park et al, supra f while probes are also described in Gonzatti- Haces et al, supra.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention décrite concerne une sonde de diagnostic servant à détecter les cancers de l'estomac chez l'homme.
PCT/US1990/007313 1989-12-27 1990-12-19 Sonde de diagnostic servant a detecter les cancers de l'estomac chez l'homme WO1991009974A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002070995A CA2070995A1 (fr) 1989-12-27 1990-12-19 Sonde diagnostique pour la detection du cancer de l'estomac chez les humains

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45755689A 1989-12-27 1989-12-27
US457,556 1989-12-27

Publications (1)

Publication Number Publication Date
WO1991009974A1 true WO1991009974A1 (fr) 1991-07-11

Family

ID=23817186

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/007313 WO1991009974A1 (fr) 1989-12-27 1990-12-19 Sonde de diagnostic servant a detecter les cancers de l'estomac chez l'homme

Country Status (5)

Country Link
EP (1) EP0507868A4 (fr)
JP (1) JPH05504476A (fr)
AU (1) AU639532B2 (fr)
CA (1) CA2070995A1 (fr)
WO (1) WO1991009974A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992020792A1 (fr) * 1991-05-10 1992-11-26 Farmitalia Carlo Erba S.R.L. Formes tronquees du recepteur de facteur de croissance des hepatocytes
WO1994000764A1 (fr) * 1992-06-26 1994-01-06 THE UNITED STATES OF AMERICA, represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES Proto-oncogene met et procede de prediction de l'evolution du cancer du sein
WO1994003196A1 (fr) * 1992-08-03 1994-02-17 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Nouvelle sonde utilisee pour diagnostiquer ou traiter des tumeurs
WO2001075169A2 (fr) * 2000-03-30 2001-10-11 Diadexus, Inc. Compositions et methodes correspondantes permettant de diagnostiquer, de surveiller, et de traiter le cancer de l'estomac ainsi que d'en former des images et en controler l'evolution
WO2002064839A2 (fr) * 2001-02-14 2002-08-22 Tularik Inc. Gene amplifie de l'hepsine associee au cancer
US6673559B1 (en) 1989-12-27 2004-01-06 The Government Of The United States Of America As Represented By The Department Of Health And Human Services Met proto-oncogene and a method for predicting breast cancer progression
US8425902B2 (en) 2007-05-29 2013-04-23 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US9068011B2 (en) 2010-03-10 2015-06-30 Genmab A+S Monoclonal antibodies against c-Met
US9212228B2 (en) 2005-11-24 2015-12-15 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US9775785B2 (en) 2004-05-18 2017-10-03 Ganymed Pharmaceuticals Ag Antibody to genetic products differentially expressed in tumors and the use thereof
US10093736B2 (en) 2012-11-13 2018-10-09 Biontech Ag Agents for treatment of claudin expressing cancer diseases
US10414824B2 (en) 2002-11-22 2019-09-17 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015568A (en) * 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FEBS Letters, Vol. 209, No. 2, issued December 1986, TEMPEST et al., "The activated human met gene encodes a protein tyrosine kinase", pages 357-361, see the entire document. *
Nucleic Acids Research, Vol. 16, No. 17, issued 1988, SWEET et al., "An EcoRI polymorphism for pMet G inbred mice", page 8745, see the entire document. *
See also references of EP0507868A4 *
THE EMBO JOURNAL, Vol. 5, No. 10 issued 1986, COOPER et al., "Amplification and overexpression of the met gene in spontaneously transformed NIH3T3 mouse fibroblasts", pages 2623-2628, see the entire document. *

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673559B1 (en) 1989-12-27 2004-01-06 The Government Of The United States Of America As Represented By The Department Of Health And Human Services Met proto-oncogene and a method for predicting breast cancer progression
WO1992020792A1 (fr) * 1991-05-10 1992-11-26 Farmitalia Carlo Erba S.R.L. Formes tronquees du recepteur de facteur de croissance des hepatocytes
EP0520158A1 (fr) * 1991-05-10 1992-12-30 PHARMACIA S.p.A. Formes tronquées du récepteur du facteur de croissance d'hépatocyte
US5571509A (en) * 1991-05-10 1996-11-05 Farmitalia Carlo Erba S.R.L. Truncated forms of the hepatocyte growth factor (HGF) receptor
WO1994000764A1 (fr) * 1992-06-26 1994-01-06 THE UNITED STATES OF AMERICA, represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES Proto-oncogene met et procede de prediction de l'evolution du cancer du sein
WO1994003196A1 (fr) * 1992-08-03 1994-02-17 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Nouvelle sonde utilisee pour diagnostiquer ou traiter des tumeurs
WO2001075169A2 (fr) * 2000-03-30 2001-10-11 Diadexus, Inc. Compositions et methodes correspondantes permettant de diagnostiquer, de surveiller, et de traiter le cancer de l'estomac ainsi que d'en former des images et en controler l'evolution
WO2001075169A3 (fr) * 2000-03-30 2003-01-23 Diadexus Inc Compositions et methodes correspondantes permettant de diagnostiquer, de surveiller, et de traiter le cancer de l'estomac ainsi que d'en former des images et en controler l'evolution
WO2002064839A2 (fr) * 2001-02-14 2002-08-22 Tularik Inc. Gene amplifie de l'hepsine associee au cancer
WO2002064839A3 (fr) * 2001-02-14 2003-02-27 Tularik Inc Gene amplifie de l'hepsine associee au cancer
US10414824B2 (en) 2002-11-22 2019-09-17 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof
US9775785B2 (en) 2004-05-18 2017-10-03 Ganymed Pharmaceuticals Ag Antibody to genetic products differentially expressed in tumors and the use thereof
US9212228B2 (en) 2005-11-24 2015-12-15 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US9499609B2 (en) 2005-11-24 2016-11-22 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US9751934B2 (en) 2005-11-24 2017-09-05 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US10017564B2 (en) 2005-11-24 2018-07-10 Ganymed Pharmaceuticals Gmbh Monoclonal antibodies against claudin-18 for treatment of cancer
US10174104B2 (en) 2005-11-24 2019-01-08 Ganymed Pharmaceuticals Gmbh Monoclonal antibodies against claudin-18 for treatment of cancer
US10738108B2 (en) 2005-11-24 2020-08-11 Astellas Pharma Inc. Monoclonal antibodies against claudin-18 for treatment of cancer
US11739139B2 (en) 2005-11-24 2023-08-29 Astellas Pharma Inc. Monoclonal antibodies against Claudin-18 for treatment of cancer
US8425902B2 (en) 2007-05-29 2013-04-23 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US9657107B2 (en) 2010-03-10 2017-05-23 Genmab A/S Monoclonal antibodies against c-Met
US9068011B2 (en) 2010-03-10 2015-06-30 Genmab A+S Monoclonal antibodies against c-Met
US11512140B2 (en) 2010-03-10 2022-11-29 Genmab A/S Monoclonal antibodies against c-Met
US10093736B2 (en) 2012-11-13 2018-10-09 Biontech Ag Agents for treatment of claudin expressing cancer diseases

Also Published As

Publication number Publication date
CA2070995A1 (fr) 1991-06-28
EP0507868A1 (fr) 1992-10-14
EP0507868A4 (en) 1992-11-04
AU7140691A (en) 1991-07-24
AU639532B2 (en) 1993-07-29
JPH05504476A (ja) 1993-07-15

Similar Documents

Publication Publication Date Title
JP3989528B2 (ja) Ｄｎａ配列及びエンコードされた乳房に特異的な乳癌たんぱく質
JP2716670B2 (ja) 抗原性オリゴペプチドの製造方法
EP0453560B1 (fr) Localisation et caracterisation du gene tumoral de wilms
EP1626084B1 (fr) Compositions et méthodes pour le diagnostic de tumeurs
JP2003518920A (ja) 新規なヒト遺伝子および遺伝子発現産物
JPH11505322A (ja) Ｔｇｆ−ベータリセプター中の変異に基づく癌の診断および治療
AU639532B2 (en) Diagnostic probe for detecting human stomach cancer
US5717067A (en) Substrate for the epidermal growth factor receptor kinase
JP4353799B2 (ja) 転移に関連するホスファターゼ
KR100566839B1 (ko) 종양 치료용 조성물 및 방법
JPWO2005028648A1 (ja) リンパ腫の病型および予後診断方法
US6387697B1 (en) Compositions for treatment and diagnosis of breast cancer and methods for their use
AU767733B2 (en) Novel transcription factor, BP1
US5942402A (en) Method of detecting and treating cancer
KR100233208B1 (ko) 림프계암 또는 상피 세포암의 예후 판정에 사용되는 핵의 인단백질
US7883896B2 (en) Marker molecules associated with lung tumors
JP2001050964A (ja) 関節炎関連メラノトランスフェリンの測定方法および試薬
JP2002506437A (ja) 癌の新規な検出および治療方法
Fushida et al. Higher frequency of ras oncogene activation in gastric stump carcinomas due to special conditions in the gastric remnant
JP2000504581A (ja) エキソン１１内のプロトオンコジーンｒｅｔの欠失の典型的ヌクレオチド配列
CA2242567A1 (fr) Test diagnostique pour determiner la malignite de tumeurs des muscles lisses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2070995

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1991902835

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991902835

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991902835

Country of ref document: EP